A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma

Inclusion Criteria: * Histologically confirmed advanced NPC * Patients must be platinum-resistant defined as recurrence or progression of disease \<6 months since previous treatment with a platinum based treatment regimen. * Measurable disease per RECIST * Adequate organ and marrow function * Capable of understanding and complying with the protocol, and written informed consent Exclusion Criteria: * Prior treatment with gefitinib, erlotinib, or other drugs that target EGFR * Patients must not be receiving any other investigational agents * Other serious illness or medical condition including unstable cardiac disease requiring treatment, history of significant neurologic or psychiatric disorders (including psychotic disorders, dementia, or seizures), or active uncontrolled infection * Women who are pregnant or breast-feeding